| Source: |
| Type: |
| Tumor Volume |
| Normal Healthy |
| 4431- | AgNPs, | doxoR, | Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | 3T3 |
| 1069- | AL, | Allicin promotes autophagy and ferroptosis in esophageal squamous cell carcinoma by activating AMPK/mTOR signaling |
| - | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | Nor, | Het-1A |
| 6496- | BCP, | β-Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models |
| - | vitro+vivo, | CRC, | HCT116 | - | in-vitro, | Nor, | HUVECs |
| 7159- | CHA, | ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin |
| - | vitro+vivo, | GC, | HGC27 | - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | HEK293 |
| 6844- | EVO, | Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70 |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 948- | Fuc, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24/HTB-9 | - | in-vitro, | Nor, | HUVECs |
| 7041- | GA, | Gallic acid suppresses the progression of clear cell renal cell carcinoma through inducing autophagy via the PI3K/Akt/Atg16L1 signaling pathway |
| - | vitro+vivo, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | Nor, | HK-2 |
| 7245- | Gink, | Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | MCF10 |
| 3152- | H2, | VitC, | Rad, | Hydrogen and Vitamin C Combination Therapy: A Novel Method of Radioprotection |
| - | in-vitro, | Nor, | HUVECs | - | in-vivo, | NA, | NA |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 5534- | MF, | Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 2258- | MFrot, | MF, | EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Nor, | SVGp12 |
| 1483- | SFN, | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| - | in-vitro, | OS, | 143B | - | in-vitro, | Nor, | HEK293 | - | in-vivo, | OS, | NA |
| 2279- | VitK2, | Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | L02 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:49 Cells:% prod#:% Target#:530 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid